GlassScriptPhysician profile
Anthony Altobelli
NPI 1003843905
$137,343.39
in general payments reported to CMS, 2019-2025
37 companies · $9,497 in 2025
The $9,497 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,875 · 2021: $19K · 2022: $18K · 2023: $33K · 2024: $34K · 2025: $9,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $5,059 · Travel and Lodging: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,410.00 |
| Food and Beverage | $5,059.13 |
| Travel and Lodging | $1,209.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52,795.53 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $44,191.85 | 2020-2024 | Nexletol, Nexlizet |
| Lilly USA, LLC | $16,968.85 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $10,583.17 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $7,888.84 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $1,043.39 | 2021-2022 | |
| Amgen INC. | $444.30 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $441.35 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Esprit |
| Boston Scientific Corporation | $386.12 | 2019-2023 | Watchman Flx, Watchman |
| Abiomed | $284.77 | 2023-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $260.16 | 2019-2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $246.53 | 2022-2025 | Camzyos |
| Ancora Heart, INC. | $245.79 | 2023-2024 | Accucinch |
| Edwards Lifesciences Corporation | $203.79 | 2023 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $166.19 | 2021-2025 | Verquvo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $131.45 | 2019-2025 | |
| Biosense Webster, INC. | $113.87 | 2023-2025 | Qdot Micro Catheter, Qdot Micro |
| Bridgebio Pharma, INC. | $89.59 | 2025 | Attruby |
| Cardiva Medical, INC. | $89.37 | 2023 | Cardiva Vascade 6/7f Vcs |
| Medtronic, INC. | $85.55 | 2024 | Micra, Aurora Ev-Icd Mri Surescan |
| Alnylam Pharmaceuticals INC. | $85.30 | 2022-2025 | Onpattro |
| Biotronik INC. | $69.88 | 2019 | |
| Gilead Sciences, INC. | $66.82 | 2019 | |
| Daiichi Sankyo INC. | $64.62 | 2022-2023 | Injectafer |
| Arbor Pharmaceuticals, INC. | $63.19 | 2020-2021 | |
| Novo Nordisk INC | $56.23 | 2025 | Wegovy |
| Amarin Pharma, INC. | $41.65 | 2019-2020 | |
| Heartflow, INC. | $40.89 | 2024-2025 | |
| Atricure, INC. | $38.30 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $28.92 | 2021-2022 | |
| Cvrx, INC. | $28.84 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $28.13 | 2021-2025 | |
| Tactile Systems Technology INC | $16.12 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $14.78 | 2024 | Arcalyst |
| Altathera Pharmaceuticals LLC | $14.33 | 2024 | Sotalol Hydrochloride |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.28 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Altobelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.